FDA Investigator Erin D Mccaffery

Erin D Mccaffery has inspections in 5 countries as of 01 Sep 2023. Erin D Mccaffery has collaborated with a combinined 5005 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:

101

Last Inspection Date:

01 Sep 2023

Investigator Role:

FDA Investigator

Redica ID:

100007357

Country:

United States of America, Canada, United Kingdom of Great Britain and Northern Ireland, Ireland

Co-Investigator(s):

Addam S Reynolds, Adetutu M Gidado, Alberto A Viciedo, Alice S Tsao, Allen Lou, Amy L Mcintyre, Amy L Singer, Amy M Codella, Amy M Cramer, Ana S Cabrera, Anastasia I Offordile, Andrew I Carr, Andrew J Barrowcliff, Anita R Michael, Ankur C Patel, Ann L Demarco, Ann Marie Montemurro, Anna Kevilag, Anna Kwilas, Annemarie B Randow, Annemarie Bodnar, Anthony Abel, Anthony C Warchut, Arsen Karapetyan, Arulvathani P Arudchandran, Ashar P Parikh, Atul J Agrawal, Azza Talaat, Barbara J Maulfair, Barbara J Wilimczyk, Barbara Jwilimczyk Macri, Barbara L Rellahan, PhD, Bernice F Hirsch, Bo Chi, PhD, Brenda S Zimmer, PhD, Bryan L Mcguckin, Byungja E Marciante, Cara M Minelli, Carl A Huffman, III, Carolyn E Barney, Cary Greene, Catherine J Laufmann, CDR Ileana Barreto Pettit, CDR Rochelle B Young, RPh, MSA, Charles J Chacko, Charles R Cote, RIC, Cheryl A Clausen, Cheryl A Grandinetti, Christina N Maurino, Christine M Cerenzio, Christopher T Middendorf, Colin E Tack, Constantin Y Philopoulos, Cynthia Jim, CSO, Daniel J Grabicki, Daniel J Min, Daniel W Johnson, David H Smith, Dawn L Wydner, Dawn M Braswell, Deborah B Goffman, Deborah B Nixon, Denise M Visco, Investigator, Dennis Cantellops Paite, Dinesh Kumar, Doan T Nguyen, PharmD, Donald L Lech, Dorothy J Denes, Douglas C Kovacs, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Emest F Bizjak, Emily A Walters, Emmanuel J Ramos, Eric J Cunningham, Eric M Mueller, PharmD, Eric Rothschild, Erin D Mccaffrery, Esteban Beltran, Farhana Khan, Francis A Guidry, Frank J Marciniak, Frank Wackes, Fred Razzaghi, Frederick Razzack, Frederick Razzaghi, George J Flynn, George Pyramides, Gianine E Tompkins, Gobiga Vanniyasingam, Guerlain Ulysse, Haitao Li, Haley H Seymour, Helen B Ricalde, Helen Verdel, Hitesh R Patel, Jacqueline Mdiaz Albertini, James C Maclaughlin, James L Finn, Janet L Bowen, Javier E Santos, Javier I Santos, Jawaid Hamid, Jay B Shah, Jean Blackstone Hill, Jean M Kelahan, Jeffrey J Ebersole, Jeffrey J, Ebersole, Jennifer D Hollstrom, Jessica L Pressley, Jing Fang, Joan A Loreng, Jogy George, Jonee J Mearns, Jose Acruz Gonzalez, Jose M Cayuela, Jose O Hernandez, Joseph F Mcginnis, RPh, Josh Renzon Ramilo, Joy R Kelna, Joy Rkozlowski Klena, Juanita P Versace, Julie D Bringger, Junho Pak, Justine Tomasso, Karen E D'orazio, Kassa Ayalew, MD, Katherine Szestypalow, Keith M Reilley, Keith M Reilly, Kelli F Dobilas, Kelli Regente, Kendra L Brooks, Kenneth V Miller, Kevin Obrien, Kevin P Foley, Kimberly L Schultz, Kinh Q Mac, Kristy A Zielny, Kshitij A Patkar, L Zam Lam, Laishan L Lam, Lakshmi Narasimhan, PhD, Larry K Austin, Lata C Mathew, PhD, Laura Fontan, MS, LCDR Debra Emerson, Li Li, Liatte Kreuger, PharmD, Liattle Krueger, Linda Thai, Lisa B Hall, Lisa Harlan, Lisa Mathew, Loretta Nemchik, Luis A Dasta, Manhar R Patel, Maotang Xhou, Maotang Zhou, PhD, Marcellinus D Dordunoo, Marcelo O Mangalindan, Jr, Margaret A Smithers, Margaret M Sands, Maria Cecilia Tami, PhD, Maria Estrella, Maria G Gutierrez Hoffman, Marjorie D Schultz, Mark E Parmon, Matthew A Spataro, Matthew B Casale, Matthew Sparato, Mayar M Mussa, Mei Chiung J Huang, Melba T Rivera, Melba Trivera Clavell, Melissa B Libby, Melissa T Roy, Merril E Racke, Meyer J Slobotsky, Michael R Klapal, Michael Serrano, Michael Shanks, MS, Michele Gottshall, Michele L Obert, Michelle A Marsh, Miguel A Martinez, Milos Dokmanovic, PhD, Monika Borkowska, Mra Davism, Mra Mcculloughj, Nancy F Scheraga, Nancy L Rolli, Nancy M Espinal, Nicholas A Violand, Niketa Patel, Nikki S Ramirez, Nimmy Mathews, Nina Yang, Niraj Mehta, Omolola A Shola Philips, Omotunde O Osunsanmi, Patricia A Cochran, Patricia H Dlugosz, Patsy J Domingo, Paul L Bellamy, Peter R Lenahan, Philip F Istafanos, DMV, MS, Prabhu P Raju, Regina T Brown, Richard H Penta, Richard Ledwidge (nmi), PhD, Richard W Thornton, Richard W Thorntton, Robert C Steyert, Robert D Tollefsen, Robert G Ruff, Robert Sharpnack, Robert W Jennings, Robin P Mathew, Rochelle K Kimmel, Rodney T Allnutt, Rose Ljean Mary, Russell J Glapion, Ruth A Williams, Sachinkumar V Patel, Saied A Asbagh, Saleem A Akhtar, Samina S Khan, Samuel T Walker, Sandra A Hughes, Sandra Kershaw, Sarah Adella Fave, Sarah E Mcmullen, Scott T Ballard, Sherri J Liu, Shirley H Isbill, Shirley J Berryman, Shirley S Wen, Sidney B Priesmeyer, Sinai Davis, Stephanie T Durso, Stephen D Brown, Stephen J Mottola, Susan O Oladeji, Susanna E Ford, Analyst, Susant Hadman, Tamil Arasu, PhD, Tania E Garcia, Tania E Vizcaino, Tara G Bizjak, Tara R Gooen, Thomas J Arista, Tonia F Bernard, Tonya R Johnson, Tracy K Li, Truong Xuan Nguyen (Andy), Tyanna N Hadley, Tynna N Hadley, Unnee Ranjan, Verlinda A Narcisse, Wayne E Seifert, Wayne J Meyer, Whitney S Reynolds, William Chang, William J Muszynski, William R Chang, Willy A Orantes, Xiaohan Cai, PhD, Xikui Chen (nmi), PhD, Xu Michael Di, PhD, Youmin Wang, Yuesheng Ye, Yumi J Hiramine, Yun Wu, PhD, Yvesna C Blaise, Yvins Dezan, Zakaria I Ganiyu, Zhihao Qiu (Peter), PhD, Zhijin Chen

Erin D Mccaffery's Documents

Publish Date	Document Type	Title
April, 2002	FDA 483	Pfizer Inc. - Form 483, 2002-04-03
September, 2001	EIR	The P.F. Laboratories Inc. - EIR, 2001-09-21
November, 2003	EIR	Ivax Pharmaceuticals Inc - EIR, 2003-11-17
June, 2004	FDA 483 Response	Pliva, Inc. - Form 483R, 2004-06-16
October, 2002	FDA 483	Warner Chilcott US LLC - Form 483, 2002-10-18
April, 2001	FDA 483	Ivax Pharmaceuticals Inc - Form 483, 2001-04-24
December, 2004	EIR	Actavis Totowa LLC - EIR, 2004-12-01
January, 2001	FDA 483 Response	Merck, Inc. - Form 483R, 2001-02-16
February, 2004	FDA 483 Response	Novus Fine Chemicals - Form 483R, 2004-03-08
January, 2010	FDA 483	CorePharma, LLC - Form 483, 2010-01-20
January, 2003	EIR	Actavis Elizabeth LLC - EIR, 2003-01-15
July, 2004	EIR	Leading Pharma, LLC - EIR, 2004-07-21
January, 2012	EIR	Actavis Elizabeth LLC - EIR, 2012-01-13
August, 2002	FDA 483	Eirchem Pharma Services Limited - Form 483, 2002-08-30
April, 2011	FDA 483	Actavis Elizabeth LLC - Form 483, 2011-04-26
September, 2004	EIR	Patheon Inc. - EIR, 2004-10-15
May, 2001	FDA 483	Sharp Corporation - Form 483, 2001-05-23
November, 2003	FDA 483	Ivax Pharmaceuticals Inc - Form 483, 2003-11-19
July, 2004	FDA 483 Response	Leading Pharma, LLC - Form 483R, 2004-08-09
June, 2005	FDA 483 Response	CELGENE CORPORATION - Form 483R, 2005-10-14
June, 2002	EIR	Sharp Corporation - EIR, 2002-06-14
March, 2010	FDA 483	CELGENE CORPORATION - Form 483, 2010-03-19
December, 2001	EIR	Hoffmann La Roche Inc - EIR, 2001-12-12
January, 2001	EIR	Merck, Inc. - EIR, 2001-01-19
February, 2008	FDA 483	Hoffmann La Roche Inc - Form 483, 2008-02-05
September, 2005	EIR	McNeil PPC Inc. - EIR, 2005-09-29
October, 2006	FDA 483 Response	Hoffmann La Roche Inc - Form 483R, 2006-11-01
September, 2000	FDA 483	Eli Lilly Co. Ltd. - Form 483, 2000-09-22
February, 2003	EIR	Hoffmann La Roche Inc - EIR, 2003-02-21
December, 2004	FDA 483	Actavis Totowa LLC - Form 483, 2004-12-01
September, 2000	FDA 483	Merck and Company - Form 483, 2000-09-13
December, 2006	FDA 483 Response	Central Admixture Pharm Services, Inc. - Form 483R, 2006-12-13
August, 2002	EIR	Eirchem Pharma Services Limited - EIR, 2002-10-03
April, 2011	EIR	Actavis Elizabeth LLC - EIR, 2011-04-26
February, 2002	FDA 483 Response	McNeil PPC Inc. - Form 483R, 2002-02-25
June, 2002	FDA 483	Sharp Corporation - Form 483, 2002-06-14
May, 2008	FDA 483	Actavis Totowa LLC - Form 483, 2008-05-20
September, 2001	FDA 483 Response	The P.F. Laboratories Inc. - Form 483R, 2001-09-26
December, 2003	FDA 483	Actavis Elizabeth LLC - Form 483, 2003-12-15
February, 2004	EIR	Novus Fine Chemicals - EIR, 2004-02-18
June, 2002	FDA 483 Response	Sharp Corporation - Form 483R, 2002-06-25
January, 2001	FDA 483	Merck & Co., Inc. - Form 483, 2001-01-19
February, 2008	EIR	Hoffmann La Roche Inc - EIR, 2008-02-05
May, 2011	FDA 483	Tris Pharma Inc - Form 483, 2011-05-06
May, 2005	EIR	Aphena Pharma Solutions - New Jersey, LLC - EIR, 2005-05-26
April, 2003	FDA 483 Response	Merck and Company - Form 483R, 2003-05-08
July, 2012	FDA 483	BRACCO DIAGNOSTICS INC - Form 483, 2012-08-06
September, 2004	FDA 483	Patheon Inc. - Form 483, 2004-09-10
March, 2009	FDA 483	Actavis Totowa LLC - Form 483, 2009-03-31
April, 2001	FDA 483 Response	Ivax Pharmaceuticals Inc - Form 483R, 2001-04-26
November, 2001	EIR	Colorcon, Inc - EIR, 2001-11-02
February, 2003	FDA 483	Hoffmann La Roche Inc - Form 483, 2003-02-21
April, 2004	FDA 483	Bayer HealthCare LLC - Form 483, 2004-04-16
June, 2012	FDA 483	CorePharma, LLC - Form 483, 2012-06-11
October, 2002	EIR	Warner Chilcott US LLC - EIR, 2002-10-18
July, 2008	FDA 483	McNeil PPC Inc. - Form 483, 2008-07-31
May, 2000	FDA 483 Response	Pfizer Inc. - Form 483R, 2000-05-23
November, 2007	FDA 483	Contract Coating Inc. - Form 483, 2007-11-06
July, 2001	FDA 483 Response	The P.F. Laboratories Inc. - Form 483R, 2001-08-02
December, 2001	FDA 483	Hoffmann La Roche Inc - Form 483, 2001-12-12
March, 2002	EIR	Hoffmann La Roche Inc - EIR, 2002-03-04
June, 2005	EIR	CELGENE CORPORATION - EIR, 2005-06-28
January, 2003	FDA 483	Actavis Elizabeth LLC - Form 483, 2003-01-15
January, 2005	FDA 483	Discovery Laboratories Inc. - Form 483, 2005-01-21
July, 2004	FDA 483	Leading Pharma, LLC - Form 483, 2004-07-21
February, 2007	FDA 483	Halo Pharmaceutical Inc - Form 483, 2007-02-22
June, 2005	FDA 483	CELGENE CORPORATION - Form 483, 2005-06-28
May, 2010	FDA 483	Cosette Pharmaceuticals, Inc. - Form 483, 2010-05-17
January, 2005	EIR	Discovery Laboratories Inc. - EIR, 2005-01-21
April, 2011	FDA 483 Response	Actavis Elizabeth LLC - Form 483R, 2011-06-15
January, 2012	FDA 483	Actavis Elizabeth LLC - Form 483, 2012-01-13
September, 2000	EIR	Eli Lilly and Company Limited - EIR, 2000-09-22
March, 2004	EIR	Health Tech Inc - EIR, 2004-03-10
August, 2002	FDA 483	Bayer HealthCare LLC - Form 483, 2002-08-02
July, 2001	EIR	The P.F. Laboratories Inc. - EIR, 2001-07-06
May, 2000	FDA 483	Pfizer Inc. - Form 483, 2000-05-11
April, 2001	EIR	Ivax Pharmaceuticals Inc - EIR, 2001-04-24
July, 2008	EIR	McNeil PPC Inc. - EIR, 2008-07-31
May, 2000	EIR	Pfizer Inc. - EIR, 2000-05-11
August, 2002	FDA 483 Response	Eirchem Pharma Services Limited - Form 483R, 2002-09-12
April, 2004	EIR	Bayer HealthCare LLC - EIR, 2004-04-16
April, 2003	FDA 483	Merck and Company - Form 483, 2003-04-17
September, 2005	FDA 483 Response	McNeil PPC Inc. - Form 483R, 2005-10-20
April, 2002	EIR	Hoffmann La Roche Inc - EIR, 2002-04-30
June, 2004	FDA 483	Pliva, Inc. - Form 483, 2004-06-02
June, 2009	FDA 483	Cosette Pharmaceuticals, Inc. - Form 483, 2009-06-18
October, 2009	FDA 483	Actavis Elizabeth LLC - Form 483, 2009-10-22
May, 2001	EIR	Sharp Corporation - EIR, 2001-05-23
October, 2006	FDA 483	Hoffmann La Roche Inc - Form 483, 2006-10-17
February, 2002	FDA 483	McNeil PPC Inc. - Form 483, 2002-02-05
December, 2003	EIR	Actavis Elizabeth LLC - EIR, 2003-12-15
June, 2004	EIR	Pliva, Inc. - EIR, 2004-06-02
January, 2013	FDA 483	GE Healthcare Inc. - Form 483, 2013-01-09
April, 2003	EIR	Merck and Company - EIR, 2003-04-17
December, 2004	FDA 483 Response	Actavis Totowa LLC - Form 483R, 2004-12-16
September, 2000	FDA 483	Eli Lilly S.A.- Irish Branch - Form 483, 2000-09-27
February, 2004	FDA 483	Novus Fine Chemicals - Form 483, 2004-02-18
December, 2006	FDA 483	Central Admixture Pharm Services, Inc. - Form 483, 2006-12-08
February, 2002	EIR	McNeil PPC Inc. - EIR, 2002-02-05
January, 2005	FDA 483 Response	Discovery Laboratories Inc. - Form 483R, 2005-01-31
December, 2003	FDA 483 Response	Actavis Elizabeth LLC - Form 483R, 2004-01-09
April, 2002	FDA 483 Response	Pfizer Inc. - Form 483R, 2002-04-22
January, 2001	FDA 483	Merck, Inc. - Form 483, 2001-01-19
September, 2005	FDA 483	McNeil PPC Inc. - Form 483, 2005-09-29
October, 2006	EIR	Hoffmann La Roche Inc - EIR, 2006-10-17
April, 2002	EIR	Pfizer Inc. - EIR, 2002-04-03
March, 2004	FDA 483	Health Tech Inc - Form 483, 2004-03-10
July, 2001	FDA 483	The P.F. Laboratories Inc. - Form 483, 2001-07-06
October, 2002	FDA 483 Response	Warner Chilcott US LLC - Form 483R, 2002-11-15
September, 2001	FDA 483	The P.F. Laboratories Inc. - Form 483, 2001-09-21
September, 2010	FDA 483	SOFIE Co. dba SOFIE - Form 483, 2010-09-14
September, 2000	FDA 483 Response	Eli Lilly and Company Limited - Form 483R, 2000-10-05

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

Total inspections conducted
483 rate
OAI rate
Warning Letter rate
Inspections by Industry, Scope, and Inspection Reason
And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

Talk to sales to access our investigator profiles

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

Pre-Approval Inspection (PAI) trends
The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
Latest 483s: see what the trends are across all FDA Investigators
CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

Full inspection histories for your vendors down to the specific site level
All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more